In addition, there is another FDA approved treatment for patients with arthritis and B cell acute lymphoblastic leukemia under CAR-T therapy, Tocilizumab, which recognizes IL-6R and disrupts the signaling cascade. This evidence concerns the gene IL6R and arthritic joint disease.